Related Experiment Video
Updated: Aug 9, 2026
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Decision analysis for avoiding postchemotherapy surgery in patients with disseminated nonseminomatous germ cell
D J Debono1, D K Heilman, L H Einhorn
1Department of Medicine, Indiana University School of Medicine, Indianapolis, USA.
Purpose:
This retrospective study was undertaken to assess the outcome of patients with disseminated nonseminomatous germ cell tumor (NSGCT) managed under a postchemotherapy strategy developed at Indiana University.
Patients And Methods:
This is a retrospective analysis of 295 consecutive patients with disseminated NSGCT treated with primary chemotherapy at Indiana University from 1987 to 1994. The patients were placed into five groups based on response to primary chemotherapy and the presence or absence of teratoma in the primary tumor. The 295 patients were divided as follows: group A (complete remission [CR]) n = 78; group B (unresectable), n = 50; group C (serologic CR, teratoma-positive primary tumor, resectable partial remission [PR]), n = 90; group D [serologic CR, teratoma-negative primary tumor, < 90% radiographic PR], n = 50; and group E (serologic CR, teratoma-negative primary tumor, > or = 90% radiographic PR), n = 27. Groups A, B, and E patients were routinely observed after chemotherapy, whereas groups C and D patients were routinely taken to postchemotherapy surgery.
Results:
The percent of patients who continuously had no evidence of disease (NED) were as follows: group A, 92%; group B, 40%; group C, 87%; group D, 86%; and group E, 74%. In assessing group A patients, the bulk of retroperitoneal disease at presentation had no influence on ultimate outcome.
Conclusion:
Patients with NSGCT who achieve a serologic and radiographic CR with primary chemotherapy (group A) can be safely observed without surgical intervention, regardless of initial tumor bulk. Patients with a teratoma-negative primary tumor who achieve a serologic CR and a > or = 90% radiographic remission and are followed-up without surgical resection (group E) are at an increased risk of relapsed NSGCT. Decisions about postchemotherapy resection in this group remain complicated and controversial. Options include observation with serial radiologic evaluation or surgical resection of persistent mass or masses.
Insights
Patients with disseminated nonseminomatous germ cell tumors (NSGCT) achieving complete remission after chemotherapy can be observed without surgery. However, those with teratoma-negative tumors and significant radiographic remission face a higher relapse risk, complicating management decisions.
Area of Science:
- Oncology
- Urology
- Medical Oncology
Background:
- Disseminated nonseminomatous germ cell tumors (NSGCT) require effective post-chemotherapy management strategies.
- Assessing outcomes based on treatment response and tumor characteristics is crucial for optimizing patient care.
Purpose of the Study:
- To evaluate the outcomes of patients with disseminated NSGCT managed with a specific post-chemotherapy strategy.
- To determine the efficacy of observation versus surgical intervention after chemotherapy for different patient subgroups.
Main Methods:
- Retrospective analysis of 295 consecutive patients with disseminated NSGCT treated from 1987 to 1994.
- Patients were categorized into five groups based on chemotherapy response, teratoma presence, and remission status.
- Management strategies included routine observation or post-chemotherapy surgery based on group classification.
Main Results:
- High rates of no evidence of disease (NED) were observed in groups achieving complete remission (CR) (92% in Group A) and those undergoing surgery (87% in Group C, 86% in Group D).
- Patients in Group E (serologic CR, teratoma-negative, > or = 90% radiographic PR) had a lower NED rate (74%) compared to other CR groups.
- Initial tumor bulk did not influence the ultimate outcome for patients in complete remission (Group A).
Conclusions:
- Observation without surgery is a safe strategy for NSGCT patients achieving complete serologic and radiographic remission post-chemotherapy.
- Patients with teratoma-negative primary tumors and significant radiographic remission (Group E) have an elevated risk of relapse, necessitating careful consideration of management options.
- The decision for post-chemotherapy resection in Group E remains complex, with options including observation or surgical intervention.
More Related Videos
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
06:46Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
